Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin
Top Cited Papers
Open Access
- 1 April 2006
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 130 (4) , 1086-1097
- https://doi.org/10.1053/j.gastro.2006.02.015
Abstract
No abstract availableKeywords
Funding Information
- Bundesministerium für Bildung und Forschung (01 KI 0102)
- F. Hoffmann-La Roche
This publication has 20 references indexed in Scilit:
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patientsJournal of Hepatology, 2004
- A 48‐Week Duration of Therapy with Pegylated Interferon α2b plus Ribavirin May Be Too Short to Maximize Long‐Term Response among Patients Infected with Genotype‐1 Hepatitis C VirusThe Journal of Infectious Diseases, 2004
- Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis CHepatology, 2003
- Extending Combination Therapy With Peginterferon Alfa–2B Plus Ribavirin for Genotype 1 Chronic Hepatitis C Late Responders: A Report of 9 CasesHepatology, 2003
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis CNew England Journal of Medicine, 2000
- Differences in Viral Dynamics between Genotypes 1 and 2 of Hepatitis C VirusThe Journal of Infectious Diseases, 2000
- Quantification of the initial decline of serum hepatitis c virus RNA and response to interferon alfaHepatology, 1998
- A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B HepatitisNew England Journal of Medicine, 1995
- Classification of chronic hepatitis: Diagnosis, grading and stagingHepatology, 1994